e- ISSN - 2348-2184
Print ISSN - 2348-2176

AMERICAN JOURNAL OF BIOLOGICAL AND PHARMACEUTICAL RESEARCH

Journal homepage: www.mcmed.us/journal/ajbpr

NEUROPHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF NEURODEGENERATIVE DISORDERS

Baskar R

Associate Professor, Department of Pharmaceutics, St. Mary's Institute of Pharmacy, Chinthamani, Puliangudi. -627855, Tamil Nadu, India.

Article Info

Received 27/02/2026
Revised 28/02/2026
Accepted 18/03/2026

Key words: -
Neuropharmacology; Neurodegenerative disorders; Alzheimer's disease; Parkinson's disease.

ABSTRACT

Neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, represent a significant global health burden characterized by progressive neuronal loss and functional decline. Advances in neuropharmacology have focused on understanding disease-specific molecular mechanisms such as protein misfiling, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Conventional therapies primarily provide symptomatic relief, while emerging strategies aim to modify disease progression. Recent developments include neuroprotective agents, monoclonal antibodies targeting pathological proteins, gene and stem cell therapies, and nanotechnology-based drug delivery systems to overcome the blood–brain barrier. Additionally, pharmacogenomics and artificial intelligence are transforming personalized treatment approaches and accelerating drug discovery. Despite these advances, challenges remain in clinical translation, long-term safety, and therapeutic efficacy. This review highlights recent neuropharmacological innovations, evaluates current therapeutic strategies, and discusses future directions for improving outcomes in neurodegenerative disorders.

INTRODUCTION

Neurodegenerative disorders constitute a heterogeneous group of chronic, progressive conditions characterized by the selective loss of neurons in the central nervous system, leading to cognitive, motor, and behavioral impairments. Among the most prevalent disorders are Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, all of which impose substantial clinical, social, and economic burdens worldwide, particularly in aging populations. The pathogenesis of these diseases is complex and multifactorial, involving mechanisms such as abnormal protein aggregation (e.g., amyloid-beta, tau, and alpha-synuclein), oxidative stress, mitochondrial dysfunction, excitotoxicity, impaired proteostasis, and chronic neuroinflammation [1]. Traditional pharmacological interventions, including cholinesterase inhibitors for Alzheimer's disease and dopaminergic therapies for Parkinson's disease, primarily provide symptomatic relief without effectively halting disease progression. Consequently, there has been an increasing focus on identifying disease-modifying therapies that can target underlying molecular pathways and prevent neuronal degeneration. Recent advances in neuropharmacology have led to the development of novel therapeutic strategies, including monoclonal antibodies, small molecule inhibitors, gene therapies, and stem cell-based approaches aimed at restoring neuronal function and slowing disease progression. Furthermore, innovative drug delivery systems, particularly nanotechnology-based platforms, have been explored to enhance drug penetration across the blood–brain barrier, a major obstacle in central nervous

Corresponding Author
Baskar R

Email: hindubaskar@gmail.com

system drug development[2]. The integration of pharmacogenomics has also enabled a more personalized approach to treatment by considering individual genetic variability in drug response and metabolism. In addition, artificial intelligence and computational modeling are revolutionizing drug discovery by facilitating target identification, lead optimization, and prediction of therapeutic outcomes. Despite these promising developments, significant challenges remain in translating preclinical findings into effective clinical therapies, largely due to disease heterogeneity, limitations in experimental models, and safety concerns associated with novel interventions. Therefore, a comprehensive understanding of neuropharmacological mechanisms and emerging therapeutic strategies is essential to advance the management of neurodegenerative disorders and improve patient outcomes.

Pathophysiology of Neurodegeneration

Neurodegeneration is a complex and multifactorial process characterized by progressive loss of neuronal structure and function, ultimately leading to cognitive and motor deficits. Central to its pathophysiology is the abnormal accumulation and aggregation of misfolded proteins such as amyloid-beta and tau in Alzheimer's disease, alpha-syncline in Parkinson's disease, and mutant huntingtin in Huntington's disease. These protein aggregates disrupt cellular homeostasis, impair synaptic function, and trigger neuronal apoptosis. Oxidative stress plays a pivotal role, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, leading to lipid peroxidation, DNA damage, and protein oxidation. Mitochondrial dysfunction further exacerbates neuronal injury by impairing ATP production and promoting apoptotic pathways.[3] Neuroinflammation, mediated by activated microglia and astrocytes, contributes significantly to disease progression through the release of pro-inflammatory cytokines and neurotoxic mediators. Additionally, excitotoxicity caused by excessive glutamate stimulation leads to calcium overload and neuronal death. Impairment of protein degradation systems, including the ubiquitin–proteasome system and autophagy–lysosomal pathways, results in the accumulation of toxic proteins. Genetic mutations and epigenetic modifications also influence disease susceptibility and progression. Furthermore, vascular dysfunction and blood–brain barrier impairment contribute to reduced nutrient supply and increased neurotoxic exposure. Collectively, these interconnected mechanisms create a vicious cycle that accelerates neuronal degeneration, highlighting the need for multi-target therapeutic strategies[4].

Neurotransmitter Dysregulation in Neurodegenerative Diseases

Neurotransmitter imbalance is a hallmark of neurodegenerative disorders and plays a crucial role in the manifestation of cognitive, motor, and behavioral symptoms. In Alzheimer's disease, a significant decline in cholinergic neurotransmission due to degeneration of basal forebrain cholinergic neurons leads to memory impairment and cognitive dysfunction. This forms the basis for the use of cholinesterase inhibitors as symptomatic treatment. In Parkinson's disease, degeneration of dopaminergic neurons in the substantia nigari pars compacta results in reduced dopamine levels, causing motor symptoms such as tremors, rigidity, and bradykinesia. Additionally, alterations in glutamatergic neurotransmission contribute to excitotoxicity, while GABAergic dysfunction disrupts inhibitory signaling, further exacerbating neuronal imbalance[5]. In Huntington's disease, there is a loss of GABAergic medium spiny neurons, leading to hyperkinetic movements and psychiatric disturbances. Serotonergic and noradrenergic systems are also affected across various neurodegenerative disorders, contributing to mood disorders, sleep disturbances, and cognitive deficits. Dysregulation of neurotransmitter receptors, transporters, and enzymes involved in synthesis and degradation further complicates neuronal communication. Moreover, neuroinflammatory processes and oxidative stress can alter neurotransmitter metabolism and receptor sensitivity[6]. The intricate interplay between different neurotransmitter systems underscores the complexity of neurodegenerative diseases and highlights the need for therapeutic approaches targeting multiple neurotransmitter pathways to restore neural network balance and improve clinical outcomes.

Conventional Pharmacotherapy: Current Standards of Care

Conventional pharmacotherapy for neurodegenerative disorders primarily focuses on symptomatic management rather than disease modification. In Alzheimer's disease, cholinesterase inhibitors such as donepezil, rivastigmine, and galantine are commonly used to enhance cholinergic transmission and improve cognitive function. Meantime, an NMDA receptor antagonist, is prescribed to reduce glutamate-mediated excitotoxicity in moderate to severe stages. In Parkinson's disease, levodopa remains the gold standard therapy, often combined with peripheral decarboxylase inhibitors to enhance its bioavailability and reduce peripheral side effects. Dopamine agonists, monoamine oxidase-B inhibitors, and catechol-O-methyl transferase inhibitors are also employed to manage motor symptoms and fluctuations[7]. For Huntington's disease, tetrabenazine and deutetrabenazine are used to control chorea by modulating dopamine levels. In amyotrophic lateral sclerosis, riluzole and edaravone are approved therapies that modestly slow disease progression

by reducing glutamate toxicity and oxidative stress, respectively. Despite their clinical utility, these treatments are limited by factors such as short-term efficacy, adverse effects, and inability to halt neuronal degeneration. Long-term use of dopaminergic therapies can lead to complications such as dyskinesia, while cholinesterase inhibitors may cause gastrointestinal disturbances. Additionally, variability in patient response and the presence of comorbidities complicate treatment outcomes.[8] Therefore, there is a pressing need for innovative therapies that not only alleviate symptoms but also target underlying disease mechanisms to achieve sustained therapeutic benefits.

Neuroprotective Strategies in Drug Development

Neuroprotective strategies in drug development aim to prevent or slow neuronal damage by targeting key pathological processes involved in neurodegeneration. One major approach involves reducing oxidative stress through the use of antioxidants that neutralize reactive oxygen species and protect cellular components from damage. Mitochondrial stabilizers are also being explored to enhance energy production and prevent apoptosis. Anti-inflammatory agents targeting microglial activation and cytokine release have shown promise in mitigating neuroinflammation, a critical contributor to neuronal injury. Another important strategy focuses on inhibiting protein aggregation and promoting clearance of toxic protein species through modulation of autophagy and proteasome pathways[9]. Neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), are being investigated for their ability to support neuronal survival, differentiation, and synaptic plasticity. Additionally, modulation of excitotoxic pathways through glutamate receptor antagonists aims to prevent calcium-mediated neuronal damage. Emerging approaches include gene therapy to correct genetic defects and RNA-based therapies to regulate disease-associated gene expression. Combination therapies targeting multiple pathways simultaneously are gaining attention due to the multifactorial nature of neurodegenerative diseases. Despite promising preclinical results, translating neuroprotective strategies into clinical success remains challenging due to issues related to drug delivery, patient heterogeneity, and the complexity of disease progression.

Role of Pharmacogenomics in Neuropharmacology

Pharmacogenomics plays a critical role in neuropharmacology by enabling personalized therapeutic approaches based on individual genetic profiles. Genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors significantly influence drug efficacy, safety, and tolerability in patients with neurodegenerative disorders. Variations in cytochrome P450 enzymes, such as CYP2D6 and CYP3A4, can affect the metabolism of commonly used neuropharmacological agents, leading to differences in plasma drug concentrations and therapeutic outcomes. Additionally, polymorphisms in genes encoding neurotransmitter receptors and transporters may alter drug response, particularly in treatments targeting dopaminergic and cholinergic systems. Pharmacogenomics testing can help identify patients who are likely to benefit from specific therapies or those at risk of adverse drug reactions, thereby optimizing treatment regimens. In Alzheimer's disease, the presence of Apo lipoprotein E (APOE) alleles has been associated with disease risk and response to certain therapies[10]. Similarly, genetic variations in Parkinson's disease can influence responsiveness to levodopa and susceptibility to side effects. Integration of pharmacogenomics data into clinical practice facilitates dose optimization, reduces trial-and-error prescribing, and enhances therapeutic precision. However, challenges such as limited accessibility, high costs, and lack of standardized guidelines hinder widespread implementation. Despite these limitations, pharmacogenomics holds significant promise in improving the safety and efficacy of neuropharmacological interventions[11].

Nanotechnology-Based Drug Delivery Systems

Nanotechnology-based drug delivery systems have emerged as a promising approach to overcome challenges associated with the treatment of neurodegenerative disorders, particularly the restricted permeability of the blood–brain barrier (BBB). Nano carriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, and Nano emulsions offer advantages including enhanced drug stability, improved bioavailability, and targeted delivery to specific brain regions. These systems can be engineered to facilitate receptor-mediated transport across the BBB, thereby increasing drug concentration at the site of action while minimizing systemic toxicity[12]. Surface modification of nanoparticles with ligands such as transferrin or antibodies enables selective targeting of neuronal cells. Additionally, Nano carriers allow for controlled and sustained drug release, reducing dosing frequency and improving patient compliance. Recent advances include the development of multifunctional nanoparticles capable of simultaneous imaging and therapy, known as theranostics. Despite their potential, concerns regarding nontoxicity, immunogenicity, and long-term safety remain significant challenges. Furthermore, large-scale manufacturing, regulatory approval, and cost-effectiveness are critical factors influencing clinical translation. Continued research in nanotechnology is essential to optimize these systems and ensure their safe and effective application in neuropharmacology[13].

Immunotherapy in Neurodegenerative Disorders

Immunotherapy has gained significant attention as a novel therapeutic approach in the management of neurodegenerative disorders by targeting pathological proteins and modulating immune responses. In Alzheimer's disease, monoclonal antibodies directed against amyloid-beta and tau proteins aim to reduce plaque formation and promote clearance of toxic aggregates. Passive immunotherapy involves the administration of preformed antibodies, while active immunotherapy stimulates the patient's immune system to generate an immune response against disease-specific antigens. In Parkinson's disease, immunotherapeutic strategies targeting alpha-syncline aggregation are under investigation to prevent neuronal toxicity[14]. These approaches have shown promise in preclinical and early clinical studies, demonstrating the potential to modify disease progression. Additionally, immunomodulatory therapies targeting neuroinflammation aim to regulate microglial activation and reduce the release of pro-inflammatory cytokines. However, challenges such as limited efficacy, risk of immune-related adverse effects, and variability in patient response remain significant barriers. The blood–brain barrier also poses a limitation to effective antibody delivery. Advances in antibody engineering, vaccine development, and combination therapies are expected to enhance the effectiveness of immunotherapy. Overall, immunotherapy represents a promising frontier in neuropharmacology, offering potential disease-modifying benefits beyond conventional symptomatic treatments[15].

CONCLUSION

Neurodegenerative disorders remain one of the most challenging areas in modern medicine due to their complex pathophysiology, progressive nature, and limited availability of curative therapies. Over the past few decades, significant advances in neuropharmacology have enhanced our understanding of the molecular and cellular mechanisms underlying these disorders, leading to the development of more targeted and sophisticated therapeutic strategies. Conventional pharmacotherapies have provided substantial symptomatic relief and improved quality of life for patients; however, their inability to halt or reverse disease progression underscores the urgent need for disease-modifying interventions. In this context, emerging approaches such as neuroprotective agents, immunotherapy, gene therapy, and stem cell-based treatments offer promising avenues for addressing the root causes of neurodegeneration. The integration of pharmacogenomics into clinical practice represents a pivotal step toward personalized medicine, enabling clinicians to tailor treatments based on individual genetic profiles and improve therapeutic outcomes while minimizing adverse effects. Furthermore, advances in nanotechnology-based drug delivery systems have shown considerable potential in overcoming the formidable challenge of the blood–brain barrier, thereby enhancing drug bioavailability and site-specific targeting within the central nervous system. The application of artificial intelligence and computational tools in drug discovery has also accelerated the identification of novel therapeutic targets and optimized drug design processes, thereby shortening development timelines. Despite these promising developments, several challenges continue to hinder the successful translation of these innovations into clinical practice. These include variability in patient response, limitations of preclinical models, safety concerns associated with novel therapies, and regulatory complexities. Additionally, the high cost of advanced therapies and limited accessibility in resource-constrained settings pose significant barriers to widespread adoption. Therefore, a multidisciplinary approach integrating pharmacology, biotechnology, computational science, and clinical research is essential to address these challenges effectively. Future research should focus on the development of multi-targeted therapies that address the multifactorial nature of neurodegenerative diseases, as well as the identification of reliable biomarkers for early diagnosis and monitoring of disease progression. Collaborative efforts among researchers, clinicians, regulatory agencies, and industry stakeholders will be crucial in advancing the field and ensuring the successful translation of innovative therapies into clinical practice. In conclusion, while considerable progress has been made in neuropharmacological research, sustained efforts and continued innovation are required to achieve meaningful disease modification and ultimately improve the lives of patients affected by neurodegenerative disorders.

REFERENCES

1. Zhang, Y. P., Kedia, S., & Klenerman, D. (2025). Rethinking neurodegeneration through a co-proteinopathy lens. *Trends in Neurosciences, 48*, 952–963.
2. Yadav, S. K., Hazari, P. P., Bhat, B., & Das, M. (2025). Current therapeutic targets and approaches in the treatment of Alzheimer's disease (pp. 25–38). CRC Press.
3. Phillippi, A., Day, H., Lupo, B., Johnson, M., Kelley, R., & Luther, P. (2024). Common mechanisms of neuronal dysfunction in neurodegenerative diseases: Insights and therapeutic strategies.
4. Huang, S., Lu, Y., Fang, W., Huang, Y., Li, Q., & Xu, Z. (2025). Neurodegenerative diseases and neuroinflammation-induced apoptosis. *Open Life Sciences, 20*, 20221051.

5. Iarkov, A., Mendoza, C., & Echeverria, V. (2021). Cholinergic receptor modulation as a target for preventing dementia in Parkinson's disease. *Frontiers in Neuroscience, 15*, 665820.
6. Koppu, N., Ch, L. K., & N, A. (2025). Neurotransmitters: Key players in neurological disorders and advances in their detection. *UPJOZ, 46*, 130–155.
7. Doraiswamy, P. M. (2025). Alzheimer's disease and the glutamate NMDA receptor. *Psychopharmacology Bulletin, 37*, 41–47.
8. Frank, S., Testa, C. M., Goldstein, J., Kayson, E., Leavitt, B. R., Oakes, D., et al. (2025). Safety and efficacy of deutetrabenazine at high versus lower daily dosages in the ARC-HD study to treat chorea in Huntington disease. *CNS Drugs, 39*, 185–195.
9. Zhao, W., Liu, Z., Wu, J., Liu, A., & Yan, J. (2025). Potential targets of microglia in the treatment of neurodegenerative diseases: Mechanism and therapeutic implications. *Neural Regeneration Research, 21*, 1497–1511.
10. Climacosa, F. M. M., Ornos, E. D. B., Gapaz, N. C. L. L., Guantia, M. G. R., Cruz, J. M. C., Manalo, R. V. M., et al. (2025). The role of genetic polymorphisms on drug response in Alzheimer's disease: A systematic review. *BMC Medical Genomics, 18*, 154.
11. Li, Y., Li, M., Wang, M., Yao, J., Li, F., Chen, S., et al. (2025). Multigenetic pharmacogenomics-guided treatment shows greater improvements on motor symptoms compared to usual therapy in Parkinson's disease: A small real-world prospective cohort study. *Frontiers in Pharmacology, 16*, 1502379.
12. Jiménez, A., Estudillo, E., Guzmán-Ruiz, M. A., Herrera-Mundo, N., Victoria-Acosta, G., Cortés-Malagón, E. M., et al. (2025). Nanotechnology to overcome blood-brain barrier permeability and damage in neurodegenerative diseases. *Pharmaceutics, 17*, 281.
13. Joseph, A., & Nance, E. (2022). Nanotherapeutics and the brain. *Annual Review of Chemical and Biomolecular Engineering, 13*, 325–346.
14. Khan, M. A., Ain Ashfaq, Q. U., Abbas, D., Munir, M. J., & Asadullah, A. (2025). Exploring immunotherapeutic approaches for Alzheimer's disease. *IJMBHR, 6*, 21–27.
15. Harris, B. (2024). Novel immunotherapies for neurodegenerative diseases. *EU Research*, Autumn 2024, 15–17.